and pharmaceutically acceptable salts thereof, where Q, R, R1 and R2 have any of the meanings defined herein. The specification also relates to the use of such compounds and salts thereof to treat or prevent GLS1 mediated disease, including cancer. The specification further relates to crystalline forms of compounds of Formula (I) and pharmaceutically acceptable salts thereof； pharmaceutical compositions comprising such compounds and salts； kits comprising such compounds and salts； methods of manufacture of such compounds and salts； intermediates useful in the manufacture of such compounds and salts； and to methods of treating GLS1 kinase mediated disease, including cancer, using such compounds and salts.
